Compare Otis Worldwide Corp (OTIS) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs Pfizer Inc — how do they compare? Otis Worldwide Corp trades at $66.12 (market cap $25.17B), while Pfizer Inc trades at $27.8 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 6.3× Otis Worldwide Corp's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Otis Worldwide Corp for 65 Days and Pfizer Inc for 158 Days on average.
| OTIS | PFE | |
|---|---|---|
Market Cap | $25.17B | $158.56B |
Volume | 4,542,442 | 44,138,282 |
Sector | Industrials | Health |
52-Week High | $93.62 | $29.02 |
52-Week Low | $64.05 | $23.67 |
Typical Hold Time | 65 Days | 158 Days |
Enterprise Value | $33.20B | $210.06B |
Dividend Yield | 2.66% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide trades at $65.74, down 1.07% on the day and near its 52-week low, reflecting bearish technical signals and recent earnings misses. The company maintains stable revenue around $14.4B USD with a net income margin of 10.17%, but faces margin pressure and a high debt-to-asset ratio of 75.54%. Recent news highlights CEO succession plans and mixed sentiment amid weak equipment demand in China.
The outlook is cautious with moderate upside to the $87.00 consensus price target, supported by a dominant service segment and institutional accumulation. Key risks include persistent margin compression, China exposure, and elevated leverage, requiring monitoring of service margin recovery for sustained growth.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
